Early or deferred cardiovascular magnetic resonance after ST-segment-elevation myocardial infarction for effective risk stratification.


Journal

European heart journal. Cardiovascular Imaging
ISSN: 2047-2412
Titre abrégé: Eur Heart J Cardiovasc Imaging
Pays: England
ID NLM: 101573788

Informations de publication

Date de publication:
01 06 2020
Historique:
received: 05 02 2019
revised: 04 04 2019
accepted: 20 06 2019
pubmed: 22 7 2019
medline: 29 6 2021
entrez: 22 7 2019
Statut: ppublish

Résumé

In ST-segment-elevation myocardial infarction (STEMI), cardiovascular magnetic resonance (CMR) holds the potentiality to improve risk stratification in addition to Thrombolysis in Myocardial Infarction (TIMI) risk score. Nevertheless, the optimal timing for CMR after STEMI remains poorly defined. We aim at comparing the prognostic performance of three stratification strategies according to the timing of CMR after STEMI. The population of this prospective registry-based study included 492 reperfused STEMI patients. All patients underwent post-reperfusion (median: 4 days post-STEMI) and follow-up (median: 4.8 months post-STEMI) CMR. Left ventricular (LV) volumes, function, infarct size, and microvascular obstruction extent were quantified. Primary endpoint was a composite of all-death and heart failure (HF) hospitalization. Baseline-to-follow-up percentage increase of LV end-diastolic (EDV; ΔLV-EDV) ≥20% or end-systolic volumes (ESV; ΔLV-ESV) ≥15% were tested against outcome. Three multivariate models were developed including TIMI risk score plus early post-STEMI (early-CMR) or follow-up CMR (deferred-CMR) or both CMRs parameters along with adverse LV remodelling (paired-CMRs). During a median follow-up of 8.3 years, the primary endpoint occurred in 84 patients (47 deaths; 37 HF hospitalizations). Early-CMR, deferred-CMR, and paired-CMR demonstrated similar predictive value for the primary endpoint (C-statistic: 0.726, 0.728, and 0.738, respectively; P = 0.663). ΔLV-EDV ≥20% or ΔLV-ESV ≥15% were unadjusted outcome predictors (hazard ratio: 2.020 and 2.032, respectively; P = 0.002 for both) but lost their predictive value when corrected for other covariates in paired-CMR model. In STEMI patients, early-, deferred-, or paired-CMR were equivalent stratification strategies for outcome prediction. Adverse LV remodelling parameters were not independent prognosticators.

Identifiants

pubmed: 31326993
pii: 5536555
doi: 10.1093/ehjci/jez179
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

632-639

Informations de copyright

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019. For permissions, please email: journals.permissions@oup.com.

Auteurs

Pier Giorgio Masci (PG)

School of Biomedical Engineering & Imaging Sciences, King's College London, St Thomas' Hospital Campus, Westminster Bridge Road, London SE1 7EH, UK.

Anna Giulia Pavon (AG)

Cardiology Division, Heart & Vessels Department, Center of Cardiac Magnetic Resonance, Rue du Bugnon 46, 1005 Lausanne, University Hospital, Lausanne, Switzerland.

Gianluca Pontone (G)

Centro Cardiologico Monzino, IRCCS Via Carlo Parea, 4, 20138 Milan, Italy.

Rolf Symons (R)

Radiology Department, Gasthuisberg University Hospitals, Herestraat 49, 3000 Leuven, Belgium.

Valentina Lorenzoni (V)

Institute of Management, Scuola Superiore Sant'Anna, Piazza Martiri della Libertà, 24, 56127 Pisa, Italy.

Marco Francone (M)

Department of Radiological, Oncological, and Pathological Sciences, La Sapienza University, Piazzale Aldo Moro, 5, 00185 Rome, Italy.

Jaroslaw Zalewski (J)

Department of Coronary Disease, Jagiellonian University Medical College, Gołębia 24, 31-007 Kraków, Poland.
Department of Interventional Cardiology, John Paul II Hospital, Prądnicka 80, 31-202 Kraköw, Poland.

Andrea Barison (A)

Fondazione CNR-Regione Toscana 'G.Monasterio', Via Moruzzi 1, 56100 Pisa, Italy.

Marco Guglielmo (M)

Centro Cardiologico Monzino, IRCCS Via Carlo Parea, 4, 20138 Milan, Italy.

Giovanni Donato Aquaro (GD)

Fondazione CNR-Regione Toscana 'G.Monasterio', Via Moruzzi 1, 56100 Pisa, Italy.

Nicola Galea (N)

Department of Radiological, Oncological, and Pathological Sciences, La Sapienza University, Piazzale Aldo Moro, 5, 00185 Rome, Italy.

Giuseppe Muscogiuri (G)

Centro Cardiologico Monzino, IRCCS Via Carlo Parea, 4, 20138 Milan, Italy.

Olivier Muller (O)

Cardiology Division, Heart & Vessels Department, Center of Cardiac Magnetic Resonance, Rue du Bugnon 46, 1005 Lausanne, University Hospital, Lausanne, Switzerland.

Iacopo Carbone (I)

Department of Radiological, Oncological, and Pathological Sciences, La Sapienza University, Piazzale Aldo Moro, 5, 00185 Rome, Italy.

Andrea Baggiano (A)

Radiology Department, Gasthuisberg University Hospitals, Herestraat 49, 3000 Leuven, Belgium.

Juan F Iglesias (JF)

Cardiology Division, University Hospitals Geneve, Rue Gabrielle-Perret-Gentil 4, 1205 Genève, Switzerland.

Jadwiga Nessler (J)

Department of Coronary Disease, Jagiellonian University Medical College, Gołębia 24, 31-007 Kraków, Poland.

Daniele Andreini (D)

Centro Cardiologico Monzino, IRCCS Via Carlo Parea, 4, 20138 Milan, Italy.

Paolo G Camici (PG)

Cardiology Division, Heart & Vessels Department, Center of Cardiac Magnetic Resonance, Rue du Bugnon 46, 1005 Lausanne, University Hospital, Lausanne, Switzerland.

Piet Claus (P)

Cardiology Department, Gasthuisberg University Hospitals, Herestraat 49, 3000 Leuven, Belgium.

Laura de Luca (L)

Cardiology Department, La Sapienza University, Piazzale Aldo Moro, 5, 00185 Rome, Italy.

Luciano Agati (L)

Cardiology Department, La Sapienza University, Piazzale Aldo Moro, 5, 00185 Rome, Italy.

Stefan Janssens (S)

Cardiology Department, Gasthuisberg University Hospitals, Herestraat 49, 3000 Leuven, Belgium.

Jurg Schwitter (J)

Cardiology Division, Heart & Vessels Department, Center of Cardiac Magnetic Resonance, Rue du Bugnon 46, 1005 Lausanne, University Hospital, Lausanne, Switzerland.

Jan Bogaert (J)

Radiology Department, Gasthuisberg University Hospitals, Herestraat 49, 3000 Leuven, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH